课题基金 / 基金详情

Pathophysiology of The Hypothalamic-pituitary-adrenal & Gonadal Axes

Pathophysiology of The Hypothalamic-pituitary-adrenal & Gonadal Axes
下丘脑-垂体-肾上腺的病理生理学
批准号:
7734695
负责人:
Tomoshige Kino
金额:
$28.87万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Tomoshige Kino的其他基金

相似基金

相关文献

中文摘要
翻译
我们寻求推进下丘脑-垂体-肾上腺(HPA)和性腺(HPG)轴的生理和病理生理的理解。应激相关激素促肾上腺皮质激素释放激素(CRH)和糖皮质激素在正常和疾病状态下的作用正在研究中,并寻求这些激素及其拮抗剂的临床应用。我们已经证明,几种人类状态的特征是中枢应激系统的活动过度或活动减退,这不仅解释了情绪变化,而且还解释了患有此类疾病的患者发展发育,代谢,心血管或自身免疫并发症的倾向。我们目前正在进行临床前研究与新发现的非肽类,口服,CRH 1型受体拮抗剂,antalarmin,这表明,这样的拮抗剂可能是有用的,在大量的状态,其特征在于过度活跃的压力系统,如抑郁症,神经性厌食症和特发性失眠。 在应激系统靶组织水平,我们通过定义糖皮质激素受体基因的新突变和/或缺失导致受体功能异常或减少,阐明了散发性和家族性糖皮质激素抵抗的分子病理生理学。在同一领域,我们描述了炎症诱导的糖皮质激素抵抗和糖皮质激素分泌不足的急性呼吸窘迫综合征。我们还发现,CLOCK/BMAL 1,在中枢神经系统和外周产生昼夜节律的自振荡转录因子,有节奏地抑制GR诱导的转录活性,表明CLOCK/BMAL 1可能通过拮抗每日波动的循环糖皮质激素的生物作用,在靶组织中起糖皮质激素作用的反相负调节剂的作用。此外,非编码(nc)RNA Gas 5,它积累在生长停滞的细胞,但其生理作用是未知的,和腺苷5单磷酸激活的蛋白激酶(AMPK),一个主调节器的能量稳态,感应体内的能量消耗和刺激途径,增加燃料摄取和节省外周供应,调节GR诱导的转录活性。前者通过充当诱饵RNA GRE来实现这一点,后者通过磷酸化GR来实现。这些结果表明HPA轴的生物学作用在靶组织水平上由营养状态和能量资源的可用性来调节。 我们已经确定,Vpr和达特,两个小的HIV-1辅助蛋白,是糖皮质激素受体的有效的共激活剂,引起显着的靶组织糖皮质激素超敏反应,其存在可能解释艾滋病的一些临床特征和发病机制。此外,我们在了解先天性肾上腺皮质增生的病理生理和治疗方面取得了进展,证明这些患者存在肾上腺素缺乏和胰岛素抵抗,这会导致卵巢功能障碍和代谢异常,而我们已经表明,雄激素拮抗剂联合芳香化酶抑制剂治疗可降低其对糖皮质激素治疗的需求,从而获得更好的身高结局。最后,我们已经证明,21-羟化酶缺乏症的携带者状态,一种常见的条件,是与显着的精神和身体疾病。最近,我们开始研究线粒体在应激反应中的参与。我们已经创建了一个人类线粒体基因数据库和微阵列芯片,并确定了糖皮质激素在肌肉细胞单胺氧化酶和氧自由基生成的调节中的主要输入。
英文摘要
We seek to advance the understanding of the physiology and pathophysiology of the hypothalamic-pituitary-adrenal (HPA) and -gonadal (HPG) axes. The roles of the stress-related hormones corticotropin-releasing hormone (CRH) and glucocorticoids in normal and disease states are being examined, and clinical applications for these hormones and their antagonists are sought. We have demonstrated that several human states are characterized by hyperactivity or hypoactivity of the central stress system, which explains not only mood changes but also the propensity of patients with such disorders to develop developmental, metabolic, cardiovascular or autoimmune complications. We are currently performing preclinical studies with the newly discovered nonpeptide, oral, CRH type 1 receptor antagonist, antalarmin, which show that such an antagonist may be useful in a large number of states characterized by hyperactivity of the stress system, such as depression, anorexia nervosa and idiopathic insomnia. At the level of the stress system target tissues, we have elucidated the molecular pathophysiology of sporadic and familial glucocorticoid resistance by defining novel mutations and/or deletions of the glucocorticoid receptor gene leading to abnormally functioning or decreased receptors. In the same area, we have described inflammation-induced glucocorticoid resistance and glucocorticoid secretion insufficiency in the acute respiratory distress syndrome. We have also found that CLOCK/BMAL1, the self-oscillating transcription factors that generate circadian rhythms in both the central nervous system and periphery, rhythmically repressed GR-induced transcriptional activity, indicating that CLOCK/BMAL1 functions as a reverse phase negative regulator of glucocorticoid action in target tissues, possibly by antagonizing the biologic actions of diurnally fluctuating circulating glucocorticoids. Furthermore, the noncoding (nc) RNA Gas5, which accumulates in growth-arrested cells, but whose physiologic roles are not known as yet, and the adenosine 5 monophosphate-activated protein kinase (AMPK), a master regulator of energy homeostasis, sensing energy depletion inside the body and stimulating pathways that increase fuel uptake and save on peripheral supplies, regulated GR-induced transcriptional activity. The former accomplished this by acting as a decoy RNA GRE, the latter by phosphorylating the GR. These results indicate that the biologic actions of the HPA axis are regulated at the level of the target tissues by the nutritional state and availability of energy resources. We have determined that Vpr and Tat, two small HIV-1 accessory proteins, are potent coactivators of the glucocorticoid receptor, causing marked target tissue glucocorticoid hypersensitivity, the presence of which may explain some of the clinical features and pathogenesis of AIDS. Also, we have made advances in understanding the pathophysiology and treatment of congenital adrenal hyperplasia, by demonstrating that these patients have epinephrine deficiency and insulin resistance, which leads to ovarian dysfunction and metabolic abnormalities, while we have shown that treatment with androgen antagonists combined with aromatase inhibitors decreases their need for glucocorticoid therapy resulting in a better height outcome. Finally, we have demonstrated that the carrier state of the 21-hydroxylase deficiency, a common condition, is associated with significant psychiatric and physical morbidity. Recently we have initiated studies examining the participation of the mitochondria in the stress response. We have created a human mitochondrial gene database and microarray chip and have determined the major input of glucocorticoids in the regulation of the enzyme monoaminoxidase and generation of oxygen radicals in muscle cells.
期刊论文(161)
专著(0)
科研奖励(0)
会议论文
Pituitary homeobox factor 1, a novel transcription factor in the adrenal regulating steroid 11beta-hydroxylase.
垂体同源盒因子 1,肾上腺调节类固醇 11β-羟化酶中的一种新型转录因子。
DOI: 10.1055/s-2003-41301
发表时间: 2003
期刊: Hormone and metabolic research. Hormon- und Stoffwechselforschung. Hormones et metabolisme
影响因子: --
作者: [Hiroi,N, Kino,T, Bassett,M, Rainey,WE, Phung,M, Abu-Asab,M, Fojo,T, Briata,P, Chrousos,GP, Bornstein,SR]
通讯作者: Bornstein,SR
Human immunodeficiency virus type-1 accessory protein Vpr: a causative agent of the AIDS-related insulin resistance/lipodystrophy syndrome?
人类免疫缺陷病毒1型辅助蛋白Vpr:艾滋病相关胰岛素抵抗/脂肪营养不良综合征的病原体?
DOI: 10.1196/annals.1321.013
发表时间: 2004
期刊: Annals of the New York Academy of Sciences
影响因子: 5.2
作者: [Kino,Tomoshige, Chrousos,GeorgeP]
通讯作者: Chrousos,GeorgeP
A patient with MEN 2 and multiple mutations of RET in the germline.
一名患有 MEN 2 且种系存在 RET 多重突变的患者。
DOI: 10.1055/s-2000-11001
发表时间: 2000
期刊: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
影响因子: --
作者: [Koch,CA, Huang,SC, Vortmeyer,AO, Zhuang,Z, Chrousos,GP, Pacak,K]
通讯作者: Pacak,K
A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators.
GR 的一种新型 C 端显性失活突变通过与 p160 类固醇受体共激活剂的异常相互作用导致家族性糖皮质激素抵抗。
DOI: 10.1210/jcem.87.6.8520
发表时间: 2002
期刊: The Journal of clinical endocrinology and metabolism
影响因子: --
作者: [Vottero,Alessandra, Kino,Tomoshige, Combe,Herve, Lecomte,Pierre, Chrousos,GeorgeP]
通讯作者: Chrousos,GeorgeP
共 55 条
    Molecular Mediators and Regulators of Glucocorticoid Actions
    Molecular Mediators and Regulators of Glucocorticoid Actions
    Molecular Mediators/Regulators of Glucocorticoid Actions
    Molecular Mediators and Regulators of Glucocorticoid Act
    国内基金
    海外基金
    基于ADK/Adenosine调控DNA甲基化探讨“利湿化瘀通络”法对2型糖尿病肾病足细胞裂孔膜损伤的干预机制研究
    • 批准号:
      82074359
    • 项目类别:
      面上项目
    • 资助金额:
      55.0万元
    • 批准年份:
      2020
    • 负责人:
      安晓飞
    • 依托单位:
    细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
    Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制